souseikai global clinical research center

For Biotech Companies

In recent years, Japan has received considerable attention from biotech companies, as it is an ideal and promising destination for finding co-development partners and licensees. One of the reasons behind this boom in popularity in Japan among foreign biotech companies is its substantial pharmaceutical market. The Japanese pharmaceutical market is the 2nd largest in the world, and market stability is expected to continue as the Japanese aging population continues to grow and the number of patients in most therapeutic areas is also steadily increasing.

There are over 350 pharmaceutical companies in Japan, and among them, 17 companies were ranked in the world’s top 100 pharma companies by drug sales in 2018.

Source: The Novasecta Global 100

When it comes to the pipelines of Japanese major pharmaceutical companies, because finding promising new drug candidates for new drugs and developing them faster than competitors are keys to success in an ever-increasing competitive industry, many Japanese pharmaceutical companies have positioned themselves in the direction of relying more on innovative biotech companies and licensing-in their assets.

It is strategically important to know at which stage Japanese pharmaceutical companies actually licensed-in assets in the past.

The below chart illustrates in which development phases Japanese Major Pharma and Global Mega Pharma licensed-in assets between 2008 and 2014. Compared to Global Mega Pharma companies, Japanese Major Pharma tended to license-in compounds in the late phases of development (28% vs 51%). Given the fact that the early phase pipeline bears higher risks of development failure, Japanese Major Pharma are more conservative when it comes to the licensing-in practices at early stages of drug development when compared to Global Mega Pharma.

What SOUSEIKAI Can Offer to Increase Out-licensing Opportunities

  • Quality Early Phase Japanese Data (from Phase 1 to POC), which are the most convincing evidence for potential Japanese partners;
  • Simultaneous Asian/Caucasian Data Collection within one protocol, which enables separate out-licensing to different regional markets while keeping the trial conduction fee at a minimum.

We are now helping biotech companies to find potential Japanese partners/investors to achieve their goals in Japan, using our extensive industry network.

For more information, please Contact Us.